{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T09:05:07Z","timestamp":1788080707739,"version":"build-2784847793"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jconrel.2024.07.045","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T03:54:33Z","timestamp":1722570873000},"page":"713-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Nano-mupirocin as tumor-targeted antibiotic: Physicochemical, immunotoxicological and pharmacokinetic characterization, and effect on gut microbiome"],"prefix":"10.1016","volume":"373","author":[{"given":"Ahuva","family":"Cern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Skoczen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsie S.","family":"Snapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atara","family":"Hod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zilbersheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaelle","family":"Bavli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Alon-Maimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Bachrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Yassour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cedrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry W.","family":"Neun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A.","family":"Dobrovolskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Clogston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan T.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechezkel","family":"Barenholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.07.045_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2013.10.029","article-title":"Computer-aided design of liposomal drugs: in silico prediction and experimental validation of drug candidates for liposomal remote loading","volume":"173","author":"Cern","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2017.02.015","article-title":"New drug candidates for liposomal delivery identified by computer modeling of liposomes\u2019 remote loading and leakage","volume":"252","author":"Cern","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0015","series-title":"Mupirocin a Novel Topical Antibiotic","first-page":"43","article-title":"Antibacterial activity of mupirocin, an antibiotic produced by Pseudomonas fluorescens","author":"White","year":"1984"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0020","doi-asserted-by":"crossref","DOI":"10.1515\/ejnm-2016-0006","article-title":"Nano-mupirocin: enabling the parenteral activity of mupirocin","volume":"8","author":"Cern","year":"2016","journal-title":"Eur. J. Nanomed."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02377-17","article-title":"In vitro susceptibility of Neisseria gonorrhoeae strains to mupirocin. An antibiotic reformulated to parenteral nano-liposomal antibiotic","author":"Cern","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2019.11.007","article-title":"Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections","author":"Goldman","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0035","first-page":"1","article-title":"Therapeutic potential of injectable nano-mupirocin liposomes for infections involving multidrug-resistant bacteria","author":"Cern","year":"2021","journal-title":"Pharmaceutics"},{"issue":"89","key":"10.1016\/j.jconrel.2024.07.045_bb0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/prd.12426","article-title":"Fusobacterium nucleatum and cancer","volume":"2000","author":"Alon-Maimon","year":"2022","journal-title":"Periodontol"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0045","article-title":"Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses","author":"Wang","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0050","series-title":"Gut microbiota\u00a0: A new piece in understanding hepatocarcinogenesis","first-page":"15","volume":"474","author":"Zhou","year":"2020"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0060","article-title":"Perturbation of the gut microbiota by antibiotics results in accelerated breast tumour growth and metabolic dysregulation","author":"Kirkup","year":"2019","journal-title":"BioRxiv Preprint"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0065","first-page":"3662","article-title":"Preexisting commensal Dysbiosis is a host- intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor \u2013 positive","volume":"79","author":"Rosean","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0070","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic Cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0075","article-title":"Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/jps.24037","article-title":"Effect of solubilizing agents on mupirocin loading into and release from PEGylated nanoliposomes","volume":"103","author":"Cern","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13010123","article-title":"Quantitative cryo-tem reveals new structural details of doxil-like pegylated liposomal doxorubicin formulation","volume":"13","author":"Nordstr\u00f6m","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0095","volume":"2021","author":"Caputo","year":"1635","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0100","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1021\/acs.molpharmaceut.6b00865","article-title":"Characterization of Pegylated liposomal Mitomycin C lipid-based prodrug (Promitil) by high sensitivity differential scanning calorimetry and cryogenic transmission Electron microscopy","volume":"14","author":"Wei","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0105","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acsomega.7b01235","article-title":"Cardinal role of Intraliposome doxorubicin-sulfate Nanorod crystal in Doxil properties and performance","volume":"3","author":"Wei","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0110","series-title":"Advanced Chemistry Development Software","year":"2024"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejpb.2016.04.011","article-title":"Insights into composition\/structure\/function relationships of Doxil\u00ae gained from \u201chigh-sensitivity\u201d differential scanning calorimetry","volume":"104","author":"Wei","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0120","article-title":"Anticoagulants influence the performance of in vitro assays intended for characterization of nanotechnology-based formulations","volume":"23","author":"Cedrone","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","article-title":"Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs","volume":"306","author":"Bavli","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: Factors promoting reactogenicity of Doxil and AmBisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jconrel.2012.02.029","article-title":"Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model","volume":"160","author":"Szebeni","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","article-title":"Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs","volume":"468","author":"Szebeni","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030558","article-title":"PEGylated liposomal methyl prednisolone succinate does not induce infusion reactions in patients: a correlation between in vitro immunological and in vivo clinical studies","volume":"25","author":"Bavli","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0155","series-title":"Mupirocin a Novel Topical Antibiotic, Royal Society of Medicin, London (Distributed by Oxford Univ. Press). International Congress and Symposium Series 80","first-page":"13","article-title":"Mupirocin: its chemistry and metabolism","author":"Baines","year":"1984"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0160","first-page":"761","article-title":"Mupirocin: a topical antibiotic with a unique structure and mechanism of action","volume":"6","author":"Parenti","year":"1987","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0165","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jconrel.2013.04.025","article-title":"Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion","volume":"172","author":"Stern","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0170","author":"CHMP"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0175","series-title":"Committee for Medicinal Products for Human Use (CHMP). CHMP Assessment Report","year":"2011"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0180","series-title":"Product Monograph Bactroban","author":"GlaxoSmithKline Inc","year":"2001"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0185","article-title":"Current understanding of antibiotic-associated dysbiosis and approaches for its management","volume":"10","author":"Kesavelu","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"2019","key":"10.1016\/j.jconrel.2024.07.045_bb0190","first-page":"1133","article-title":"The gut microbiota and colon cancer","volume":"364","author":"Garrett","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0195","series-title":"Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration","first-page":"1","volume":"13","author":"Casasanta","year":"2020"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.chom.2016.07.006","article-title":"Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed gal-GalNAc","volume":"20","author":"Abed","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2017.00295","article-title":"Tumor targeting by Fusobacterium nucleatum: a pilot study and future perspectives","volume":"7","author":"Abed","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0210","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.18632\/oncotarget.3109","article-title":"Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0215","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1158\/1078-0432.CCR-16-1786","article-title":"Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis","volume":"22","author":"Yamamura","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0220","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1158\/1078-0432.CCR-19-0318","article-title":"Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma","volume":"25","author":"Yamamura","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0225","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","article-title":"Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis","volume":"65","author":"Mima","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16967-2","article-title":"Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression","volume":"11","author":"Parhi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0235","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109886","article-title":"Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models","volume":"37","author":"Dong","year":"2021","journal-title":"Cell Rep."},{"issue":"2017","key":"10.1016\/j.jconrel.2024.07.045_bb0245","first-page":"1443","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0250","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3343\/alm.2022.42.2.188","article-title":"Clinical differences in patients infected with fusobacterium and antimicrobial susceptibility of fusobacterium isolates recovered at a tertiary-care hospital in Korea","volume":"42","author":"Kim","year":"2022","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0255","doi-asserted-by":"crossref","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","author":"L\u00f6fmark","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1634\/theoncologist.2019-0160","article-title":"Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer","volume":"25","author":"Tinsley","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0265","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0270","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.21037\/atm.2019.10.27","article-title":"Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer","volume":"7","author":"Reed","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0275","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jac\/dks379","article-title":"The enhanced permeability retention effect: a new paradigm for drug targeting in infection","volume":"68","author":"Azzopardi","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0280","series-title":"Characterization of Nanoparticles Intended for Drug Delivery","first-page":"149","article-title":"Analysis of complement activation by nanoparticles","author":"Neun","year":"2018"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0285","author":"Neun"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0290","author":"Potter"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0295","author":"Cedrone"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0300","author":"Neun"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0305","series-title":"Characterization of Nanoparticles Intended for Drug Delivery","first-page":"103","article-title":"In vitro assessment of nanoparticle effects on blood coagulation","author":"Potter","year":"2018"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0310","series-title":"Characterization of Nanoparticles Intended for Drug Delivery","first-page":"225","article-title":"Method for in vitro analysis of nanoparticle thrombogenic properties","author":"Neun","year":"2011"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0315","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0320","series-title":"Solymos, Vegan: Community Ecology Package","author":"Oksanen","year":"2022"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0325","series-title":"ggplot2, Springer New York, New York, NY","author":"Wickham","year":"2009"},{"key":"10.1016\/j.jconrel.2024.07.045_bb0330","unstructured":"A. Kassambara, ggplot2, Based Publication Ready Plots (2023). https:\/\/rpkgs.datanovia.com\/ggpubr\/authors.html."},{"key":"10.1016\/j.jconrel.2024.07.045_bb0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jac\/dkl181","article-title":"In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria","volume":"58","author":"Altman","year":"2006","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T20:56:01Z","timestamp":1725742561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":67,"alternative-id":["S0168365924005005"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.045","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nano-mupirocin as tumor-targeted antibiotic: Physicochemical, immunotoxicological and pharmacokinetic characterization, and effect on gut microbiome","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}